Voyager Therapeutics - VYGR Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $14.00
Forecasted Upside: 91.78%
Number of Analysts: 1
Breakdown:
0 Sell Ratings
0 Hold Ratings
1 Buy Ratings
0 Strong Buy Ratings

^$7.30 As of 03/24/2023 12:52 PM ET

▼ -0.18 (-2.41%)

1 month | 3 months | 12 months

Get New Voyager Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for VYGR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VYGR

^$14.00

▲ +91.78% Upside Potential

This price target is based on 1 analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 91.78% upside from the last price of $7.30.

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Voyager Therapeutics. This rating has held steady since October 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

9/30/2021

0 strong buy ratings
4 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

12/29/2021

0 strong buy ratings
3 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/29/2022

0 strong buy ratings
2 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/27/2022

0 strong buy ratings
1 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/25/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/24/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/22/2023

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/24/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/9/2023	Oppenheimer	Initiated Coverage	Outperform	$14.00	Low
3/9/2022	Chardan Capital	Boost Target		$4.00 ➝ $6.00	High
1/3/2022	UBS Group	Lower Target		$14.00 ➝ $6.00	High
11/2/2021	Chardan Capital	Lower Target	Neutral	$5.50 ➝ $4.00	Low
10/7/2021	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$6.00 ➝ $9.00	Medium
8/11/2021	Benchmark	Lower Target	Buy	$20.00 ➝ $9.00	Low
7/1/2021	Chardan Capital	Reiterated Rating	Neutral		High
6/21/2021	Compass Point	Initiated Coverage	Buy	$45.00	Low
5/13/2021	Robert W. Baird	Reiterated Rating	Hold	$6.00	High
4/19/2021	Morgan Stanley	Lower Target	Equal Weight	$7.00 ➝ $6.00	Medium
3/1/2021	Robert W. Baird	Reiterated Rating	Outperform ➝ Buy	$18.00	Low
2/26/2021	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$18.00 ➝ $6.00	High
2/3/2021	Wedbush	Downgrade	Outperform ➝ Neutral	$13.00 ➝ $6.00	High
2/3/2021	Morgan Stanley	Lower Target	Equal Weight ➝ Hold	$13.00 ➝ $7.00	High
2/3/2021	Chardan Capital	Lower Target	Neutral	$15.00 ➝ $6.50	High
2/3/2021	BTIG Research	Downgrade	Buy ➝ Neutral		High
1/25/2021	HC Wainwright	Initiated Coverage	Buy	$12.00	Medium
12/23/2020	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$15.00 ➝ $10.00	N/A
12/23/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		N/A
11/11/2020	BTIG Research	Lower Target		$31.00 ➝ $18.00	High
11/11/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High
11/10/2020	Wedbush	Lower Target	Outperform	$19.00 ➝ $13.00	High
11/10/2020	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$10.00	High
11/10/2020	Raymond James	Downgrade	Strong-Buy ➝ Outperform	$28.00 ➝ $17.00	High
10/13/2020	Wedbush	Lower Target	Hold ➝ Outperform	$24.00 ➝ $19.00	High
8/14/2020	Chardan Capital	Reiterated Rating	Hold	$15.00	Medium
8/12/2020	Wedbush	Reiterated Rating	Buy	$24.00	Low
8/4/2020	HC Wainwright	Lower Target	Buy	$18.00 ➝ $14.00	High
5/13/2020	Nomura	Reiterated Rating	Buy	$16.00	Low
5/8/2020	Chardan Capital	Reiterated Rating	Hold	$15.00	Low
4/15/2020	Morgan Stanley	Lower Target	Equal Weight	$14.00 ➝ $13.00	Low
3/30/2020	Nomura Securities	Lower Target	Buy	$37.00 ➝ $16.00	High
3/19/2020	Benchmark	Initiated Coverage	Buy	$18.00	High
3/6/2020	Chardan Capital	Reiterated Rating	Hold	$20.00	High
3/4/2020	HC Wainwright	Lower Target	Buy	$26.00 ➝ $18.00	Medium
3/4/2020	Morgan Stanley	Lower Target	Equal Weight	$15.00 ➝ $14.00	Medium
3/4/2020	Wedbush	Lower Target	Outperform	$34.00 ➝ $27.00	High
2/5/2020	Oppenheimer	Initiated Coverage	Outperform	$26.00	High
11/24/2019	Evercore ISI	Reiterated Rating	Hold	$18.00	Medium
11/6/2019	Wedbush	Reiterated Rating	Outperform		Medium
11/6/2019	Cowen	Reiterated Rating	Buy		High
10/15/2019	Cowen	Reiterated Rating	Buy		Low
10/11/2019	Morgan Stanley	Lower Target	Equal Weight	$28.00 ➝ $26.00	Low
8/13/2019	Nomura Securities	Reiterated Rating	Buy	$37.00	High
8/12/2019	HC Wainwright	Reiterated Rating	Buy	$26.00	Medium
7/12/2019	Morgan Stanley	Boost Target	Equal Weight	$21.00 ➝ $28.00	Medium
6/20/2019	Nomura Securities	Boost Target	Buy	$26.00 ➝ $37.00	High
6/18/2019	Wedbush	Boost Target	Outperform	$27.00 ➝ $36.00	High
5/6/2019	HC Wainwright	Reiterated Rating	Buy	$22.00	Medium
3/5/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$27.00	High
2/27/2019	Cowen	Reiterated Rating	Buy		High
1/15/2019	HC Wainwright	Reiterated Rating	Buy	$21.00	High
1/10/2019	Chardan Capital	Reiterated Rating	Neutral		Medium
1/8/2019	BTIG Research	Lower Target	Buy ➝ Positive	$23.00	Low
11/30/2018	HC Wainwright	Set Target	Buy	$25.00	Low
11/9/2018	HC Wainwright	Set Target	Buy	$25.00	Medium
11/8/2018	Robert W. Baird	Lower Target	Outperform ➝ Outperform	$31.00 ➝ $27.00	High
11/8/2018	Morgan Stanley	Set Target	Hold	$13.00	High
11/8/2018	Wedbush	Reiterated Rating	Outperform	$18.00 ➝ $28.00	High
9/10/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal		High
9/10/2018	Morgan Stanley	Reiterated Rating	Overweight ➝ Equal Weight	$27.00	High
9/10/2018	BTIG Research	Reiterated Rating	Buy ➝ Buy	$32.00	Medium
8/8/2018	HC Wainwright	Set Target	Buy	$30.00	High
7/17/2018	HC Wainwright	Set Target	Buy	$30.00	High
6/21/2018	Chardan Capital	Reiterated Rating	Hold	$30.00	High
6/7/2018	BTIG Research	Reiterated Rating	Buy	$32.00	Low
6/4/2018	HC Wainwright	Initiated Coverage	Buy	$30.00	High
5/13/2018	BTIG Research	Reiterated Rating	Buy		High
5/11/2018	Wedbush	Upgrade	Neutral ➝ Outperform		High

(Data available from 3/24/2018 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

4 very positive mentions
13 positive mentions
2 negative mentions
2 very negative mentions

Mentions as of

8/26/2022

2 very positive mentions
20 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

9/25/2022

5 very positive mentions
6 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

10/25/2022

3 very positive mentions
11 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/24/2022

2 very positive mentions
11 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

12/24/2022

5 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/23/2023

1 very positive mentions
1 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/22/2023

3 very positive mentions
17 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

3/24/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Today's Range

Now: $7.30

$7.11

$7.44

50 Day Range

MA: $8.16

$6.92

$10.78

52 Week Range

Now: $7.30

$4.61

$10.81

Volume

120,981 shs

Average Volume

431,761 shs

Market Capitalization

$316.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Voyager Therapeutics?: The following equities research analysts have issued stock ratings on Voyager Therapeutics in the last year: Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for VYGR.
What is the current price target for Voyager Therapeutics?: 1 Wall Street analysts have set twelve-month price targets for Voyager Therapeutics in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 91.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting VYGR will reach $14.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $14.00 for Voyager Therapeutics in the next year.
View the latest price targets for VYGR.
What is the current consensus analyst rating for Voyager Therapeutics?: Voyager Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VYGR will outperform the market and that investors should add to their positions of Voyager Therapeutics.
View the latest ratings for VYGR.
What other companies compete with Voyager Therapeutics?: Other companies that are similar to Voyager Therapeutics include Tarsus Pharmaceuticals, Autolus Therapeutics, Poseida Therapeutics, Humacyte and DBV Technologies. Learn More about companies similar to Voyager Therapeutics.
How do I contact Voyager Therapeutics' investor relations team?: Voyager Therapeutics' physical mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company's listed phone number is (857) 259-5340 and its investor relations email address is [email protected] The official website for Voyager Therapeutics is www.voyagertherapeutics.com. Learn More about contacing Voyager Therapeutics investor relations.

Voyager Therapeutics - VYGR Stock Price Target and Predictions

Analyst Price Target for VYGR

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.37 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Voyager Therapeutics?

What is the current price target for Voyager Therapeutics?

What is the current consensus analyst rating for Voyager Therapeutics?

What other companies compete with Voyager Therapeutics?

How do I contact Voyager Therapeutics' investor relations team?